Advanced Nanomedicine: Redefining Therapeutic Paradigms for Inflammatory Bowel Disease

被引:22
作者
Zhang, Yinfeng [1 ,2 ]
Wang, Tingting [2 ]
Sun, Meng [3 ]
Song, Yueyue [3 ]
Huang, Xinyuan [1 ]
Zhang, Shutian [1 ]
Yang, Jun [4 ]
Zhang, Jinfeng [3 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Natl Clin Res Ctr Digest Dis, Dept Gastroenterol,Beijing Key Lab Precancerous Le, Beijing 100050, Peoples R China
[2] Capital Med Univ, Beijing Friendship Hosp, Int Med Ctr, Beijing 100050, Peoples R China
[3] Beijing Inst Technol, Sch Life Sci, Key Lab Mol Med & Biotherapy, Beijing 100081, Peoples R China
[4] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China
基金
中国国家自然科学基金;
关键词
gut microbiota; inflammatory bowel disease (IBD); macrophage polarization; nanotherapeutics; reactive oxygen species (ROS); REACTIVE OXYGEN METABOLITES; ULCERATIVE-COLITIS; GUT MICROBIOTA; TNF-ALPHA; INTESTINAL ORGANOIDS; DELIVERY; NANOPARTICLES; THERAPIES; IMMUNITY; IBD;
D O I
10.1002/adhm.202300069
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Inflammatory bowel disease (IBD), a chronic and recurrent gastrointestinal inflammatory disorder with a variety of painful clinical manifestations and an increased risk of cancerization or death, has become an emerging challenge to global healthcare due to its rapidly increasing incidence. At present, there is no efficient cure against IBD because of the elusive etiology and pathogenesis of IBD. Therefore, the development of alternative therapeutic strategies with positive clinical efficacy and reduced side effects is urgently needed. In recent years, the great prosperity of nanomedicine promoted by a variety of advanced nanomaterials is redefining more attractive and promising therapeutic strategies for IBD owing to their advantages in the physiological stability, bioavailability, and targeting of inflammatory sites. In this review, firstly the basic characteristics of healthy and inflammatory intestinal microenvironments are presented. Then, different administration routes and targeting strategies of nanotherapeutics for IBD treatment are reviewed. Subsequently, a specific focus is placed on the introduction of nanotherapeutic treatments based on different IBD pathogenesis. Finally, some future challenges and perspectives of the currently developed nanomedicines for IBD treatment are provided. It is believed that the above topics will attract researchers from various fields including medicine, biological sciences, materials, chemistry and pharmaceutics.
引用
收藏
页数:21
相关论文
共 50 条
  • [41] Extracellular Vesicles: The Next Generation Theranostic Nanomedicine for Inflammatory Bowel Disease
    Li, De-feng
    Yang, Mei-feng
    Xu, Jing
    Xu, Hao-ming
    Zhu, Min-zheng
    Liang, Yu-jie
    Zhang, Yuan
    Tian, Cheng-mei
    Nie, Yu-qiang
    Shi, Rui-yue
    Wang, Li-sheng
    Yao, Jun
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2022, 17 : 3893 - 3911
  • [42] Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response
    Elhag, Duaa Ahmed
    Kumar, Manoj
    Saadaoui, Marwa
    Akobeng, Anthony K.
    Al-Mudahka, Fatma
    Elawad, Mamoun
    Al Khodor, Souhaila
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [43] The potential therapeutic role of vitamin D in inflammatory bowel disease
    Boccuzzi, L.
    Infante, M.
    Ricordi, C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (10) : 4678 - 4687
  • [44] The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre
    Hart, A. L.
    Hendy, P.
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2014, 73 (04) : 452 - 456
  • [45] Metallothionein: A Novel Therapeutic Target for Treatment of Inflammatory Bowel Disease
    Dostie, Kristen E.
    Thees, Amy V.
    Lynes, Michael A.
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (27) : 3155 - 3161
  • [46] Inflammatory bowel disease: long-term therapeutic challenges
    Ashton, James J.
    Green, Zachary
    Kolimarala, Vinod
    Beattie, R. Mark
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (11) : 1049 - 1063
  • [47] Postbiotics in inflammatory bowel disease: efficacy, mechanism, and therapeutic implications
    Wang, Shuxin
    Wang, Pu
    Wang, Donghui
    Shen, Shenghai
    Wang, Shiqi
    Li, Yuanyuan
    Chen, Hao
    JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE, 2025, 105 (02) : 721 - 734
  • [48] The microbiota in inflammatory bowel disease
    Sheehan, Donal
    Moran, Carthage
    Shanahan, Fergus
    JOURNAL OF GASTROENTEROLOGY, 2015, 50 (05) : 495 - 507
  • [49] The Microbiome in Inflammatory Bowel Disease
    Jauregui-Amezaga, Aranzazu
    Smet, Annemieke
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
  • [50] Isoflavones and inflammatory bowel disease
    Wu, Ze-Yu
    Sang, Li-Xuan
    Chang, Bing
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (11) : 2081 - 2091